



PB 82 of 2025

National Health (Minimum Stockholding) Amendment Determination (No. 6) 2025

I, Rebecca Richardson, as delegate of the Minister for Health and Ageing, make the following determination.

Dated 25 June 2025

Rebecca Richardson
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health, Disability and Ageing

Contents

1 Name	1
2 Commencement.....	1
3 Authority	1
4 Schedules.....	1
Schedule 1—Amendments commencing 1 July 2025	2
<i>National Health (Minimum Stockholding) Determination 2023</i>	2
Schedule 2—Amendments commencing 1 October 2025	6
<i>National Health (Minimum Stockholding) Determination 2023</i>	6

1 Name

- (1) This instrument is the *National Health (Minimum Stockholding) Amendment Determination (No. 6) 2025*.
- (2) This instrument may also be cited as PB 82 of 2025.

2 Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table	1 July 2025.	1 July 2025
2. Schedule 1	1 July 2025.	1 July 2025
3. Schedule 2	1 October 2025.	1 October 2025

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 99AEKC(2) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments commencing 1 July 2025

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

After:				
Amisulpride	Oral solution 100 mg per mL, 60 mL	Oral	Solian Solution	4 months stock by reference to usual PBS demand
insert:				
Amisulpride	Tablet 400 mg	Oral	Amipride 400	between 1 July 2025 to 31 August 2025—0 months stock by reference to usual demand

2 Schedule 1 (table)

After:				
Ceftriaxone	Powder for injection 2 g (as sodium)	Injection	Ceftriaxone Viatris	after 31 May 2024—6 months stock by reference to usual demand of both Ceftriaxone Viatris and Ceftriaxone Alphapharm added together
insert:				
Celecoxib	Capsule 100 mg	Oral	Blooms the Chemist Celecoxib	between 1 July 2025 to 31 August 2025—0 months stock by reference to usual demand

3 Schedule 1 (table)

Omit:				
Doxorubicin	Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 200 mg in 100 mL single dose vial	Injection/Intravesical	Adriamycin	between 1 June 2025 and 30 June 2025—0 months stock by reference to usual demand

4 Schedule 1 (table)

Omit:

Ezetimibe with simvastatin	Tablet 10 mg-10 mg	Oral	Zeklen 10/10 mg	between 1 April 2025 and 30 June 2025— 0 months stock by reference to usual demand
----------------------------	--------------------	------	-----------------	---

5 Schedule 1 (table)

Omit:

Ezetimibe with simvastatin	Tablet 10 mg-20 mg	Oral	Zeklen 10/20 mg	between 1 April 2025 and 30 June 2025— 0 months stock by reference to usual demand
----------------------------	--------------------	------	-----------------	---

6 Schedule 1 (table)

Omit:

Ezetimibe with simvastatin	Tablet 10 mg-40 mg	Oral	Zeklen 10/40 mg	between 1 April 2025 and 30 June 2025— 0 months stock by reference to usual demand
----------------------------	--------------------	------	-----------------	---

7 Schedule 1 (table)

Omit:

Ezetimibe with simvastatin	Tablet 10 mg-80 mg	Oral	Zeklen 10/80 mg	between 1 April 2025 and 30 June 2025— 0 months stock by reference to usual demand
----------------------------	--------------------	------	-----------------	---

8 Schedule 1 (table)

After:

Fluconazole	Powder for oral suspension 50 mg in 5 mL, 35 mL	Oral	Diflucan	4 months stock by reference to usual PBS demand
-------------	---	------	----------	---

insert:

Fluorouracil	Injection 5000 mg in 100 mL	Injection	Fluorouracil Ebewe	between 1 July 2025 to 31 July 2025— 0 months stock by reference to usual demand
--------------	-----------------------------	-----------	--------------------	---

9 Schedule 1 (table)

After:

Glyceryl trinitrate	Transdermal patch 54 mg	Transdermal	Minitran 15	between 1 February 2025 and 31 December 2025— 0 months stock by reference to usual demand
---------------------	----------------------------	-------------	-------------	--

insert:

Granisetron	Concentrated injection 3 mg (as hydrochloride) in 3 mL	Injection	Granisetron-AFT	between 1 July 2025 to 31 July 2025— 0 months stock by reference to usual demand
-------------	---	-----------	-----------------	--

10 Schedule 1 (table)

Omit:

Hypromellose with carbomer 980	Ocular lubricating gel 3 mg-2 mg per g, 10 g	Application to the Eye	Genteal gel	between 1 October 2024 and 30 June 2025—0 months stock by reference to usual demand
-----------------------------------	--	---------------------------	-------------	---

Hypromellose with carbomer 980	Ocular lubricating gel 3 mg-2 mg per g, 10 g	Application to the Eye	HPMC PAA	between 1 October 2024 and 30 June 2025—0 months stock by reference to usual demand
-----------------------------------	--	---------------------------	----------	---

11 Schedule 1 (table)

After:

Irbesartan with hydrochlorothiazide	Tablet 150 mg-12.5 mg	Oral	AVSARTAN HCT 150/12.5	4 months stock by reference to usual demand
--	--------------------------	------	--------------------------	---

insert:

Irbesartan with hydrochlorothiazide	Tablet 150 mg-12.5 mg	Oral	Blooms the Chemist Irbesartan HCTZ 150/12.5	between 1 July 2025 to 31 August 2025— 0 months stock by reference to usual demand
--	--------------------------	------	---	--

Irbesartan with hydrochlorothiazide	Tablet 300 mg-12.5 mg	Oral	Blooms the Chemist Irbesartan HCTZ 300/12.5	between 1 July 2025 to 31 August 2025— 0 months stock by reference to usual demand
--	--------------------------	------	---	--

12 Schedule 1 (table)

Omit:

Sumatriptan	Tablet 50 mg (as succinate)	Oral	Imigran	between 1 April 2025 and 30 June 2025— 0 months stock by reference to usual demand
Sumatriptan	Tablet 50 mg (as succinate)	Oral	Imigran Migraine	between 1 April 2025 and 30 June 2025— 0 months stock by reference to usual demand

13 Schedule 1 (table)

After:

Vancomycin	Powder for injection 500 mg (500,000 I.U.) (as hydrochloride)	Injection	Vancomycin Viatrix	4 months stock by reference to usual demand of both Vancomycin Viatrix and Vancomycin Alphapharm added together
Vinorelbine	insert: Solution for I.V. infusion 50 mg (as tartrate) in 5 mL	Injection	Navelbine	between 1 July 2025 to 31 August 2025— 0 months stock by reference to usual demand

Schedule 2—Amendments commencing 1 October 2025

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

Omit:				
Acarbose	Tablet 50 mg	Oral	Acarbose Viatris	after 30 July 2024— 4 months stock by reference to usual demand of both Acarbose Viatris and Acarbose Mylan added together

2 Schedule 1 (table)

Omit:				
Azithromycin	Tablet 500 mg (as dihydrate)	Oral	Azithromycin Viatris	after 30 September 2024—4 months stock by reference to usual demand of both Azithromycin Viatris and Azithromycin Mylan added together

3 Schedule 1 (table)

Omit:				
Cefazolin	Powder for injection 2 g (as sodium)	Injection	Cephazolin Viatris	after 30 July 2024— 6 months stock by reference to usual demand of both Cephazolin Viatris and Cephazolin Alphapharm added together
substitute:				
Cefazolin	Powder for injection 2 g (as sodium)	Injection	Cephazolin Viatris	6 months stock by reference to usual demand

4 Schedule 1 (table)

Omit:				
Ceftriaxone	Powder for injection 2 g (as sodium)	Injection	Ceftriaxone Viatris	after 31 May 2024— 6 months stock by reference to usual demand of both Ceftriaxone Viatris and Ceftriaxone Alphapharm added together
substitute:				
Ceftriaxone	Powder for injection 2 g (as sodium)	Injection	Ceftriaxone Viatris	6 months stock by reference to usual demand

5 Schedule 1 (table)

Omit:				
Entecavir	Tablet 1 mg (as monohydrate)	Oral	Entecavir Viatris	after 28 February 2025— 4 months stock by reference to usual demand of both Entecavir Viatris and Entecavir Mylan added together

6 Schedule 1 (table)

Omit:				
Lercanidipine	Tablet containing lercanidipine hydrochloride 20 mg	Oral	ARX- LERCANIDIPINE	6 months stock by reference to usual demand of both Lercanidipine APOTEX and ARX- LERCANIDIPINE added together
substitute:				
Lercanidipine	Tablet containing lercanidipine hydrochloride 20 mg	Oral	ARX- LERCANIDIPINE	6 months stock by reference to usual demand

7 Schedule 1 (table)

Omit:				
Montelukast	Tablet, chewable, 5 mg (as sodium)	Oral	APX-Montelukast	4 months stock by reference to usual demand of both Montelukast APOTEX and APX- Montelukast added together

8 Schedule 1 (table)

Omit:				
Olanzapine	Tablet 10 mg	Oral	APO-OLANZAPINE	4 months stock by reference to usual demand of both Olanzapine APOTEX and APO-OLANZAPINE added together

9 Schedule 1 (table)

Omit:				
Tenofovir	Tablet containing tenofovir disoproxil maleate 300 mg	Oral	Tenofovir Disoproxil Viartis	after 31 January 2025— 4 months stock by reference to usual demand of both Tenofovir Disoproxil Viartis and Tenofovir Disoproxil Mylan added together

10 Schedule 1 (table)

Omit:				
Tenofovir with emtricitabine	Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg	Oral	TENOFOVIR/EMT RICITABINE 300/200 ARX	3 months stock by reference to usual demand of both Tenofovir/Emtricitabine 300/200 APOTEX and TENOFOVIR/EMT RICITABINE 300/200 ARX added together
substitute:				
Tenofovir with emtricitabine	Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg	Oral	TENOFOVIR/EMT RICITABINE 300/200 ARX	3 months stock by reference to usual demand